# Triumeq As an Integrase Single Tablet Regimen in People With HIV Who Inject Drugs

> **NCT02659761** · PHASE4 · TERMINATED · sponsor: **University College Dublin** · enrollment: 33 (actual)

## Conditions studied

- Human Immunodeficiency Virus

## Interventions

- **DRUG:** dolutegravir/abacavir/lamivudine

## Key facts

- **NCT ID:** NCT02659761
- **Lead sponsor:** University College Dublin
- **Sponsor class:** OTHER
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2016-11
- **Primary completion:** 2021-09
- **Final completion:** 2021-09
- **Target enrollment:** 33 (ACTUAL)
- **Why stopped:** Sponsor decision due to slow recruitment rates and no future recruitment foreseen
- **Last updated:** 2024-05-09

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02659761

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02659761, "Triumeq As an Integrase Single Tablet Regimen in People With HIV Who Inject Drugs". Retrieved via AI Analytics 2026-07-13 from https://api.ai-analytics.org/clinical/NCT02659761. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*